RegeneRx Biopharmaceuticals, Inc. Receives Australian Patent for Compositions and Methods for Delivering Tß4 and Its Analogues and Derivatives

BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) (the “Company” or “RegeneRx”) announced today that it received an Australian patent covering certain compositions and methods for delivery of Thymosin beta 4 (Tß4), its analogues, isoforms and other derivatives for increasing the local concentration of such compounds at wounded or injured sites in the body. The patent expires in 2024.
MORE ON THIS TOPIC